Abstract
Objectives
The observation of numerous new structural defects in hemoglobin (Hb) has often been linked to the evolution and development of device technologies used for the separation and quantification of hemoglobin components. However, the increased use of preventive tests for hemoglobinopathies and separative methods to quantify glycated hemoglobin (HbA1c) also contributed to these observations, as demonstrated by the case described here. Our aim is to emphasize that different separative method can provide more useful information in patient management.
Methods
A 64-year-old diabetic woman of Moroccan descent was examined in the context of HbA1c monitoring. The test was performed using high performance liquid chromatography (HPLC) and capillary electrophoresis (CE) systems. Molecular characterization was performed by direct sequencing of the β and α globin genes.
Results
The two methods used showed the presence of an anomalous fraction identified as HbS, already observed previously, but only through CE it was possible to observe the presence of another variant and its hybrid components. Direct sequencing of β and α globin genes confirmed heterozygous HbS [β6 (A3) Glu→Val; HBB: c.20A>T] and allowed to identify a mutation on the α2, [α114 (GH2) Pro→Leu gene; HBA2: c.344C>T] corresponding to the rare Hb Nouakchott variant.
Conclusions
The two Hb variants highlighted by the EC and the molecular characterization therefore allowed adequate advice, the correct assessment of HbA1c and metabolic status and therefore better clinical management of the patient. The availability of different instruments in the same laboratory, confirming situations of diagnostic uncertainty, represents a valuable opportunity that should be encouraged.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest. The authors alone are responsible for the content and writing of this article. Sauro Maoggi is Scientific Affairs Manager in Sebia-Italia.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. Barberio Giuseppina, Ivaldi Giovanni for Società Italiana Talassemie ed Emoglobinopatie. Societa’ Italiana Talassemie Ed Emoglobinopatie. Raccomandazioni per la diagnostica di primo livello delle emoglobinopatie-SITE; 2012. Available from: http://www.site-italia.org/collana_scientifica.php.Search in Google Scholar
2. Traeger-Synodinos, J, Harteveld, CL, Old, JM, Petrou, M, Galanello, R, Giordano, P, et al.. EMQN best practice guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. Eur J Hum Genet 2015;23:426–37. https://doi.org/10.1038/ejhg.2014.131.Search in Google Scholar
3. Haj Khelil, A, Denden, S, Leban, N, Daimi, H, Lakhdhar, R, Lefranc, G, et al.. Hemoglobinopathies in North Africa: a review. Hemoglobin 2010;34:1–23. https://doi.org/10.3109/03630260903571286.Search in Google Scholar
4. Piel, FB, Patil, AP, Howes, RE, Nyangiri, OA, Gething, PW, Dewi, M, et al.. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142–51. https://doi.org/10.1016/s0140-6736(12)61229-x.Search in Google Scholar
5. Venturelli, D, Lodi, M, Palazzi, G, Bergonzini, G, Doretto, G, Zini, A, et al.. Sickle cell disease in areas of immigration of high-risk populations: a low cost and reproducible method of screening in northern Italy. Blood Transfus 2014;12:346–51. https://doi.org/10.2450/2013.0188-13.Search in Google Scholar
6. De Franceschi, L. La drepanocitosi: un problema emergente di salute pubblica. Ematologia Pediatr 2014;44:88–95.Search in Google Scholar
7. Dodé, C, Rochette, J, Krishnamoorthy, R. Locus assignment of human alpha globin mutations by selective amplification and direct sequencing. Br J Haematol 1990;76:275–81.10.1111/j.1365-2141.1990.tb07884.xSearch in Google Scholar
8. Carta, M, Paleari, R, Caldini, A, Terreni, A, Mosca, A. Refertazione dell’emoglobina glicata in presenza di varianti emoglobiniche. Biochim Clin 2011;35:42–5.Search in Google Scholar
9. Strickland, SW, Campbell, ST, Little, RR, Bruns, DE, Bazydlo, LAL. Recognition of rare hemoglobin variants by hemoglobin A1c measurement procedures. Clin Chim Acta 2018;476:67–74. https://doi.org/10.1016/j.cca.2017.11.012.Search in Google Scholar
10. Steinberg, MH, Forget, BG, Higgs, DR, Nagel, RL. Disorders of hemoglobin: genetics, pathophysiology, and clinical management, 2nd ed. Cambridge: Cambridge University Press; 2009.10.1017/CBO9780511596582Search in Google Scholar
11. Steinberg, MH, Adams, JG3rd, Dreiling, BJ. Alpha thalassaemia in adults with sickle-cell trait. Br J Haematol 1975;30:31–7. https://doi.org/10.1111/j.1365-2141.1975.tb00514.x.Search in Google Scholar
12. Thomas, PW, Higgs, DR, Serjeant, GR. Benign clinical course in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol 1997;50:121–6. https://doi.org/10.1016/s0895-4356(96)00320-4.Search in Google Scholar
13. Stevens, MC, Maude, GH, Beckford, M, Grandison, Y, Mason, K, Taylor, B, et al.. Alpha thalassemia and the hematology of homozygous sickle cell disease in childhood. Blood 1986;67:411–4. https://doi.org/10.1182/blood.v67.2.411.411.Search in Google Scholar
14. Thom, CS, Dickson, CF, Gell, DA, Weiss, MJ. Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med 2013;3:a011858. https://doi.org/10.1101/cshperspect.a011858.Search in Google Scholar
15. Noguchi, CT, Rodgers, GP, Schechter, AN. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals. Prog Clin Biol Res 1987;240:381–91.Search in Google Scholar
16. Lawrence, C, Hirsch, RE, Fataliev, NA, Patel, S, Fabry, ME, Nagel, RL. Molecular interactions between Hb alpha-G philadelphia, HbC, and HbS: phenotypic implications for SC alpha-G philadelphia disease. Blood 1997;90:2819–25. https://doi.org/10.1182/blood.v90.7.2819.Search in Google Scholar
17. Préhu, C, Riou, J, Godart, C, Bost, M, Barro, C, Promé, D, et al.. Hb diamant [alpha119(H2) Pro→Leu]: a new variant with a modification at the α1β1 interface. Hemoglobin 2000;24:249–52. https://doi.org/10.3109/03630260008997533.Search in Google Scholar
18. Wajcman, H, Delaunay, J, Francina, A, Rosi, J, Galactéros, F. Hemoglobin Nouakchott [alpha 114(GH2) Pro→Leu]: a new hemoglobin variant displaying an unusual increase in hydrophobicity. Biochim Biophys Acta 1989;998:25–31. https://doi.org/10.1016/0167-4838(89)90114-3.Search in Google Scholar
19. Pondman, KM, Brinkman, JW, van der Straaten, HM, Stroobants, AK, Harteveld, CL. Hb Nouakchott [α114(GH2) Pro→Leu; HBA1: c.344C>T], a second and third case described in two unrelated Dutch families. Hemoglobin 2018;42:51–3. https://doi.org/10.1080/03630269.2018.1429280.Search in Google Scholar PubMed
20. Harteveld, CL, van Delft, P, Plug, R, Versteegh, FGA, Hagen, B, van Rooijen, I. Hb Groene Hart: a new Pro→Ser amino acid substitution at position 119 of the α1-globin chain is associated with a mild α-thalassemia phenotype. Hemoglobin 2002;26:255–60. https://doi.org/10.1081/hem-120015029.Search in Google Scholar PubMed
21. Zanella-Cleon, I, Becchi, M, Lacan, P, Giordano, PC, Wajcman, H, Francina, A. Detection of a thalassemic alpha-chain variant (hemoglobin Groene Hart) by reversed-phase liquid chromatography. Clin Chem 2008;54:1053–9. https://doi.org/10.1373/clinchem.2007.097857.Search in Google Scholar PubMed
© 2022 Walter de Gruyter GmbH, Berlin/Boston
